Takeda

  • Takeda Taps Insilico for $600M AI Drug Discovery Partnership AGI

    Takeda Taps Insilico for $600M AI Drug Discovery Partnership

    Takeda Pharmaceutical Company has partnered with Insilico Medicine to leverage AI for early-stage drug discovery. The collaboration grants Takeda access to Insilico’s Pharma.AI platform, accelerating target identification and molecular design. Takeda secures exclusive development and commercialization rights, with Insilico eligible for up to $600 million in milestone payments and royalties. This alliance highlights the growing trend of AI integration in pharmaceutical research.

    2026年7月3日
  • Takeda's Zasocitinib: Landmark Phase 3 Trial Shows Potential for Clear Skin in Plaque Psoriasis with Once-Daily Oral Treatment Markets

    Takeda’s Zasocitinib: Landmark Phase 3 Trial Shows Potential for Clear Skin in Plaque Psoriasis with Once-Daily Oral Treatment

    Takeda’s oral TYK2 inhibitor, zasocitinib, demonstrated strong efficacy in Phase 3 psoriasis trials, meeting all primary and secondary endpoints. The drug achieved significant skin clearance, with many patients experiencing substantial improvement and complete skin clearance by week 16. Zasocitinib showed a consistent safety profile and is poised for regulatory submission in fiscal year 2026, offering a promising new oral treatment option for moderate-to-severe plaque psoriasis.

    2026年2月13日